CPHI
China Pharma Holdings, Inc.1.4400
-0.0900-5.88%
Dec 16, 3:59:56 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.23MP/E (TTM)
-Basic EPS (TTM)
-1.02Dividend Yield
0%Recent Filings
8-K
10-Q
10-Q
Q2 FY2025 results
China Pharma's Q2 revenue climbed 11% year-over-year to $1.0M, fueled by gains in anti-viral and cardio products amid market swings, while six-month sales dipped 5.8% to $2.2M. Gross margins sharpened to -8.5% from -109.8% y/y, thanks to lower PP&E amortization and inventory provisions, yet operating losses narrowed to $0.65M from $1.39M. EPS improved to -$0.16, aligning with 3.26M diluted shares post-reverse split. Cash held steady at $0.6M, with $0.23M operating inflow offsetting $0.09M capex for $0.14M free cash flow (derived); lines of credit totaled $2.0M at 3.25-3.6%, backed by CEO guarantees. Losses narrowed, but going concern doubts linger. Customer concentration risks persist.
10-Q
Q1 FY2025 results
China Pharma's Q1 revenue dipped 17% year-over-year to $1.14M, driven by softer sales in anti-viral and respiratory products amid centralized procurement pressures, yet gross loss narrowed to $0.14M from $0.29M as costs fell 23% to $1.27M, lifting the gross margin to -12.0% from -21.2%. Operating loss improved 17% to $0.76M, with expenses steady at $0.62M despite higher intangible amortization; net loss eased to $0.79M or $(0.24) per diluted share on 3.26M shares, versus $(0.72) last year. Cash drained to $0.41M after $0.06M operating outflow, but lines of credit totaling $2.33M at 3.25%-3.9% rates, backed by CEO guarantees and facility collateral, provide breathing room alongside $1.15M related-party borrowings. No M&A or non-GAAP metrics disclosed in the 10-Q. Regulatory hurdles in generic consistency evaluations pose ongoing risks.
8-K
Reverse split details
China Pharma Holdings announced a 1-for-10 reverse stock split, effective April 15, 2025, converting every 10 pre-split shares into one post-split share with no fractional shares issued—instead rounded up. Approved by shareholders on December 22, 2024, and set at this ratio by the board on March 26, 2025, the move aims to adjust share structure while preserving ownership percentages. Trading continues under CPHI on NYSE American. Yet risks like market volatility persist.
IPO
Employees
Sector
Industry
AMPH
Amphastar Pharmaceuticals, Inc.
25.61-0.70
BGM
BGM Group Ltd.
5.01-0.16
COSM
Cosmos Health Inc.
0.50+0.09
CWBHF
Charlotte's Web Holdings Inc.
0.15+0.00
RGC
Regencell Bioscience Holdings L
16.70-0.56
SBFM
Sunshine Biopharma Inc.
1.38-0.01
SXTC
China SXT Pharmaceuticals, Inc.
1.64+0.19
TEVA
Teva Pharmaceutical Industries
30.10-0.03
UPC
Universe Pharmaceuticals Inc
3.68+0.05
VTRS
Viatris Inc.
11.46-0.20